Fig. 5
MLN4924 and VP work together to inhibit YAP1-targeted gene expression of GCs. A?C, GCs were treated with VP at various doses (0, 0.1, 0.5, 1, 5, 10 ?M) for 24 h. Cell lysates were subjected to Western blotting, and the protein levels of YAP1 and Birc5 were quantified and normalized to that of ?-actin. A, representative experiment from three separate experiments is shown. B, quantification of YAP1 protein expression level in VP-treated cells. C, quantification of Birc5 protein expression level in VP-treated cells. D?G, qPCR analysis of YAP1-activated target genes Birc5 (D) and CTGF (E) mRNA levels, and YAP1-inhibited target genes SFN (F) and GADD45A (G) mRNA levels in GCs treated with DMSO, ML4924 (1 ?M), VP (5 ?M), or ML4924 and VP together for 24 h. H?J, GCs were treated with DMSO, ML4924, VP, or ML4924 and VP together for 24 h. Cell lysates were used for Western blot, and CTGF and Birc5 protein levels were subsequently quantified and normalized to that of ?-actin. A representative Western blot (H), the quantification of CTGF (I) and Birc5 (J) from three independent experiments. Data are presented as means ± SD, ?p < 0.05, ??p < 0.01, and ???p < 0.001. DMSO, dimethyl sulfoxide; GC, granulosa cell; ns, not significant; qPCR, quantitative real-time PCR; VP, verteporfin; YAP1, yes-associated protein 1. |